Further to the notification made on 10 September 2020, Benchmark Holdings is
pleased to announce that the MRL (Maximum Residue Limit) for its novel sea lice
treatment BMK08 has now been ratified under European Law. The MRL confirms the
safety of Benchmark's sea lice solution for consumers and represents a
significant milestone in the regulatory approval process towards the anticipated
commercial launch of BMK08 and CleanTreat in Norway. The commercial launch
remains subject to the grant of a Marketing Authorisation in Norway.   

BMK08 and CleanTreat is a transformational solution addressing the biggest
biological challenge in salmon farming. The MRL EU ratification is the
culmination of almost a decade of research and development, a rigorous trial
programme and substantial capital investment by Benchmark.  
 
Trond Williksen, CEO, commented:
 
"The ratification of the MRL is a further stepping stone towards
commercialisation following the announcement of our first customer agreements
for CleanTreat  announced in March. 

Sea lice continues to be the biggest biological challenge for salmon producers
and Benchmark's novel solution addresses this challenge in a sustainable way
both in terms of animal welfare and environmental impact."

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange